Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context

Badrinath R. Konety, Vikram M. Narayan, Colin P.N. Dinney

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


High-risk non–muscle invasive bladder cancer is marked by frequent disease recurrences and risk of stage progression, contributing to high surveillance, treatment-related costs, and patient anxiety. Although the mainstay of high-risk non–muscle invasive bladder cancer clinical management remains transurethral resection followed by intravesical bacillus Calmette-Guérin (BCG), patients who develop BCG-unresponsive disease have few salvage options outside of a radical cystectomy with pelvic lymphadenectomy. This article provides a historical context relevant to the development of the BCG-unresponsive definition, an overview of current clinical trial expectations, and an introduction to this issue of Urologic Clinics.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalUrologic Clinics of North America
Issue number1
StatePublished - Feb 2020


  • BCG failure
  • BCG-unresponsive disease
  • Definitions of BCG-unresponsive
  • High-risk non–muscle invasive bladder cancer
  • Salvage intravesical therapy
  • Society of Urologic Oncology Clinical Trials Consortium

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context'. Together they form a unique fingerprint.

Cite this